Efficacy and Safety of Probiotics and Synbiotics in Liver Transplantation

This article summarizes available literature regarding the utilization of probiotic and synbiotics in liver transplant (LTX) recipients, reviewing efficacy in both decreasing infectious complications and immunomodulation, as well as exploring safety concerns. Data suggest that the use of probiotics...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2018-07, Vol.38 (7), p.758-768
Main Authors: Jorgenson, Margaret R., Descourouez, Jillian L., Siodlak, Magdalena, Tjugum, Shelby, Rice, John P., Fernandez, Luis A.
Format: Article
Language:English
Subjects:
Animal models
Case reports
Complications
Damage prevention
Damage tolerance
Graft rejection
Immunological tolerance
Immunomodulation
infectious disease
Ischemia
Liver
Liver transplantation
Liver transplants
Probiotics
Reperfusion
Safety
transplant
Transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article summarizes available literature regarding the utilization of probiotic and synbiotics in liver transplant (LTX) recipients, reviewing efficacy in both decreasing infectious complications and immunomodulation, as well as exploring safety concerns. Data suggest that the use of probiotics containing Lactobacillus spp, either alone or in combination with prebiotics (referred to as synbiotics), may be effective in reducing infectious complications after LTX, a major contributor to graft loss, hospital length of stay, and mortality. Literature evaluating the use of probiotics to induce tolerance, reduce rejection, and prevent damage associated with ischemia–reperfusion injury is limited to animal models but compelling, as it suggests the use of probiotics may augment deleterious immune‐mediated processes in this population. While the benefits of probiotics should be weighed against potential risks, these concerns are largely theoretical in the LTX recipient, with the majority of evidence extrapolated from case reports in other immunosuppressed populations. Based on available literature, it may be prudent to avoid products containing Saccharomyces sp, as these were not used in the efficacy studies, and the majority of the adverse event reporting stems from the use of products containing this organism. Further evaluation of the safety and efficacy of probiotic therapy is warranted. Studies specifically designed to elucidate the optimal product and initiation scenario and delineate safety in this population are needed to allow expanded use of this inexpensive, relatively nontoxic, and potentially beneficial therapeutic option after LTX.
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.2130